Navigation Links
Sunesis Presents Data Supporting SNS-032's Potential Anticancer,Activity in Multiple Myeloma at the American Association for Cancer,Research Meeting

were presented today as part of the Targeted Agents and Other Novel Therapies session in poster "SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226" (Abstract #1815).

About SNS-032

SNS-032 is a potent and selective inhibitor of CDKs 2, 7 and 9, which are critical in the communication and relay of signals to promote cellular growth and function. CDK2 is involved in cellular proliferation by regulating the initiation of and progression through the DNA-synthesis phase of the cell cycle. CDK7 and CDK9 are involved in transcriptional regulation of certain proteins involved in cell survival. Inappropriate activity by these CDKs can lead to unregulated proliferation, avoidance of apoptosis and increased cell survival, all of which are hallmarks of cancer. By selectively targeting these CDKs, SNS-032 may halt both aberrant cell proliferation and induce apoptosis.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute myeloid leukemia for its lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitor compound, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314 is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has buil
'"/>




Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
(Date:3/2/2015)... 2015 Attorney Advertising -- Bronstein, Gewirtz ... behalf of purchasers of the securities of Vitae ... VTAE -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether Vitae Pharmaceuticals and certain of its officers ...
(Date:3/2/2015)... 2015  CANTEL MEDICAL CORP. (NYSE: CMN ... CEO, will be presenting at the Sidoti & Company ... presentation is scheduled for 2:00 PM ET on Monday, ... New York . In addition, Mr. Krakauer, ... be available for separate one-on-one meetings during the day. ...
(Date:3/2/2015)... 2, 2015  CytomX, a biotechnology company developing ... announced the creation of scientific and clinical advisory ... the fields of cancer immunotherapy and antibody drug ... will provide guidance to CytomX on the development ... and Probody drug conjugates. The company identified advisors ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
(Date:3/2/2015)... 02, 2015 The minimally invasive ... a CAGR of 6.1% to reach $14,133.0 million ... , Factors such as advantages of minimally invasive ... owing to minimally invasive surgeries and increasing number ... driving the global minimally invasive surgical instruments market. ...
(Date:3/2/2015)... Wailea, Maui Hawaii (PRWEB) March 02, 2015 ... Five-Star resort, is celebrating its 25th anniversary this year, having ... commemorate the milestone, the luxury resort is honoring over 70 ... at the resort -- from amongst the approximately 400 original ... dinner on the Resort’s Oceanfront Lawn. , This ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The Alliance ... fire safety expert Mark Chubb to serve as chief ... safety operations and training in Bangladesh and guide remediation ... , “Mark will ensure that the Alliance continues ... safety programs for Bangladesh garment workers,” said Alliance Independent ...
(Date:3/2/2015)... Minneapolis, Minnesota (PRWEB) March 02, 2015 ... a new strategic relationship with First Protective Insurance ... new initiative will allow First Protective affiliated advisors ... and implementation support that Secura Consultants delivers. ... is a national leader in the design and ...
(Date:3/1/2015)... Metamora, Michigan (PRWEB) March 01, 2015 ... approved to treat Overactive Bladder (OAB) symptoms, such as a ... adults when another type of medication (anticholinergic) does not work ... different treatment option that takes another approach to targeting the ... BOTOX® works on the nerves and bladder muscle, blocking the ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... BruxZir Solid Zirconia, ... bridge with no porcelain overlay. This new restoration proves strong, reliable and esthetic because of ... ... innovation from Glidewell Dental Lab , is a full-contour solid zirconia crown or bridge ...
... ... thought his story was worth telling. After being diagnosed with Parkinson,s disease ... a manuscript about the experience. Not only could he not find a ... even reading sample chapters. Believing the story needed to be told, Bill ...
... , ... an Atlanta based antivirus company specializing in threat prevention and cloud based antivirus solutions, ... powered mobile devices operate cross carrier and worldwide with Google reporting 60,000 Android handsets ... ...
... ... 32nd Annual National Martial Arts Festival at the Cherry Hill Crowne Plaza Hotel in Cherry Hill, ... (PRWEB) July 1, 2010 -- ... movies, head to Cherry Hill, N.J. The U.S. Soo Bahk Do Moo Duk Kwan Federation, ...
... is already one of medicine,s most successful transplant procedures, ... Now, for the first time, a team of German ... of transplanted corneas are more likely in patients whose ... to surgery. The meta-analysis report appears in July ...
... PA, July 1, 2010 About 1 in 200 women ... 75% of these low-risk, single-baby births planned in advance as ... American Journal of Obstetrics & Gynecology ( AJOG ... results of multiple studies from around the world. They report ...
Cached Medicine News:Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 2Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 3Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 4Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 2Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 3Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 4Health News:Bluepoint Security Launches World's First Cloud Antivirus For The Google Android Mobile Platform 2Health News:700 Karate Kids to Converge on Cherry Hill, NJ July 8-10, 2010 2Health News:Study finds new key to corneal transplant success 2Health News:Planned home births associated with tripling of neonatal mortality rate vs. planned hospital births 2
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
Medicine Products: